Sugi Predict

Sugi Predict / Compounds / SCHEMBL2291255

SCHEMBL2291255

SCHEMBL2291255

CSc1ccc(OC(=O)OC(Cl)C(C)C)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 3/20 0.36
▸ AKR1C2 P52895 3/20 0.36
▸ ACACB O00763 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ RAB9A P51151 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ PLK1 P53350 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ MMP2 P08253 2/20 0.33
▸ MMP9 P14780 2/20 0.33
▸ CYP1A1 P04798 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP1B1 Q16678 1/20 0.33
▸ ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2287443 0.87 AKR1C3 (0.37) AKR1C3AKR1C2ACACBMAPTNPSR1
SCHEMBL16003902 0.82 KMT2A (0.42) MAPTNPSR1LMNARAB9AMEN1
SCHEMBL15984595 0.82 LMNA (0.48) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL15987227 0.82 SMN1; SMN2 (0.42) LMNARAB9AMEN1KMT2ACYP1A2
SCHEMBL15987228 0.81 ALDH1A1 (0.41) MAPTKDM4EMEN1KMT2AMMP2
SCHEMBL15987288 0.79 MAPT (0.47) MAPTNPSR1LMNAPOLBRAB9A
SCHEMBL9351782 0.79 MEN1 (0.50) AKR1C3AKR1C2MAPTNPSR1KDM4E
SCHEMBL16702786 0.78 ACACB (0.38) AKR1C3AKR1C2ACACBMAPTNPSR1
SCHEMBL10434505 0.78 AKR1C3 (0.36) AKR1C3AKR1C2ACACBMAPTNPSR1
SCHEMBL20537070 0.78 KMT2A (0.46) ACACBMAPTNPSR1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516023-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2026-01-06 — — US disclosed
EP-4001272-B1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2024-11-13 — — EP disclosed
US-20240082417-A1 PROTEIN-POLYMER DRUG CONJUGATES ASANA BIOSCIENCES, LLC 2024-03-14 — — US disclosed
US-20230183326-A1 PROTEIN-POLYMER-DRUG CONJUGATES ASANA BIOSCIENCES, LLC 2023-06-15 — — US disclosed
US-20230183326-A1 PROTEIN-POLYMER-DRUG CONJUGATES ASANA BIOSCIENCES, LLC 2023-06-15 — — US disclosed
US-20230183326-A1 PROTEIN-POLYMER-DRUG CONJUGATES ASANA BIOSCIENCES, LLC 2023-06-15 — — US disclosed
US-11434278-B2 Protein-polymer-drug conjugates ASANA BIOSCIENCES, LLC (US) 2022-09-06 — — US disclosed
EP-4001272-A1 NMDA ANTAGONIST PRODRUGS Astrazeneca AB (SE) 2022-05-25 — — EP disclosed
EP-3564234-B1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2021-09-29 — — EP disclosed
US-20210040039-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2021-02-11 — — US disclosed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 — — US disclosed
US-7989641-B2 Methods of synthesizing N-hydroxysuccinimidyl carbonates XENOPORT, INC. (US) 2011-08-02 — — US disclosed
US-7989641-B2 Methods of synthesizing N-hydroxysuccinimidyl carbonates XENOPORT, INC. (US) 2011-08-02 — — US disclosed
US-7989641-B2 Methods of synthesizing N-hydroxysuccinimidyl carbonates XENOPORT, INC. (US) 2011-08-02 — — US disclosed
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-04-08 — — US disclosed
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-04-08 — — US disclosed
US-20100081830-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-04-01 — — US disclosed
US-20100081830-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-04-01 — — US disclosed
WO-2010017498-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-02-11 — — WO disclosed
WO-2010017504-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS CPS1, ASNS, NAAA AKR1C3 466/4885AKR1C2 585/4885ACACB 212/4885
US-20210040039-A1 NMDA ANTAGONIST PRODRUGS GRIN1, GRIN2A, GRIN3A AKR1C3 3604/4885AKR1C2 3547/4885ACACB 4660/4885
US-20100081830-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES CPS1, SI, ASNS AKR1C3 412/4885AKR1C2 433/4885ACACB 617/4885
US-20230183326-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, STAMBP, TSPO AKR1C3 3945/4885AKR1C2 3931/4885ACACB 3769/4885
US-11434278-B2 Protein-polymer-drug conjugates PBRM1, STAMBP, TSPO AKR1C3 3945/4885AKR1C2 3931/4885ACACB 3769/4885
US-20240082417-A1 PROTEIN-POLYMER DRUG CONJUGATES PBRM1, STAMBP, TSPO AKR1C3 3931/4885AKR1C2 3940/4885ACACB 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.